skip to Global Navigation Bar skip to main content


homeHome > R&D > Pipeline

 Pipeline

Pipeline
Category Product Indication Development Status
R PC PI P II P III PR M
NCE DWP05195 Neuropathic pain
DWP10292 Non alcoholic fatty liver
DWP09031 Alzheimer's disease
DWJ208 Chronic pain
DWJ205 Fungal infection
DWJ206 Gastric ulcer
DWJ303 Contrast Agent
DWJ209 lung cancer, Pancreatic cancer
Biologics Easyef (Nepidermin) Diabetic foot ulcer
Acute wounds
Oral mucositis
Dressing combination
NOVOSIS
(rhBMP-2)
Dental bonegraft
Spinal fusion
Nabota
(Botulinum toxin type A)
Glabellar lines
Nabota Next Glabellar lines        
post-stroke upper limb spasticity
DWP457 Type 1 and 2 Diabetes        
IMD
Nurigra Chewable Tablet Erectile Dysfuction
Megavec 400mg Leukemia
DWJ1308 Antiemetic      
DWJ1341 Anodynia    
DWJ1355 Thrombosis        
Sustained Release DWJ1365 Dementia      
DWJ1261 Thrombosis
DWJ1303 Antipsychotics      
DWJ1335 Antiulcer        
FDC Olostar Hypertension, Hyperlipidemia
DWJ1325 Antiulcer      
DWJ1330 Hyperlipidemia        
DWJ1351 Hypertension, Hyperlipidemia        
DWJ1340 Antitussive, Mucolytic Agents        
DWJ1366 Antiulcer        
DWJ1367 GERD        
API DWJ630 Contrast media
DWJ625 Carbapenem antibiotics
DWJ637 Antidepressant
DWJ638 Carbapenem antibiotics
DWJ639 Hypertension
DWJ643 Asthma
DWJ632 Hepatitis B
DWP634 Carbapenem antibiotics

R : Research, PC : Pre-clinical Study, P1 : Phase 1 Clinical Study, P2 : Phase 2 Clinical Study

P3 : Phase 3 Clinical Study, PR : Pre-registration, M : Marketed

NCE: New Chemical Entity IMD: Incrementally Modified Drugs API: Active Pharmaceutical Ingredient